Stifel Reiterates Buy on Iovance Biotherapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Benjamin Burnett has reiterated a 'Buy' rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a price target of $25.
September 15, 2023 | 12:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst has reiterated a 'Buy' rating on Iovance Biotherapeutics and maintained a price target of $25.
The reiteration of a 'Buy' rating by a Stifel analyst and the maintenance of a $25 price target indicates a positive outlook for Iovance Biotherapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100